Mark Hertzberg
- Hematology top 0.5%
- Hematopoietic Stem Cell Transplantation 23
- Acute Myeloid Leukemia Research 16
- Platelet Disorders and Treatments 15
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 36
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 67
- Oncology top 1%
- CAR-T cell therapy research 17
- Viral-associated cancers and disorders 14
- Immunology top 5%
-
- Acute Lymphoblastic Leukemia research 15
- Co-authors
- Emmanuel J. FavaloroDavid GottliebIan KerridgeAlex F. HerreraMuhıt ÖzcanLaurie H. SehnMatthew J. MatasarTae Min Kim
- Journals
- Blood (41 papers)Journal of Clinical Oncology (16 papers)Bone Marrow Transplantation (7 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Mark Hertzberg
156 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 105
- Hematology 1.1k
- Genetics 894
- Pathology and Forensic Medicine 1.5k
- Oncology 1.7k
- Immunology 605
Countries citing papers authored by Mark Hertzberg
This map shows the geographic impact of Mark Hertzberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Hertzberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Hertzberg more than expected).
Fields of papers citing papers by Mark Hertzberg
This network shows the impact of papers produced by Mark Hertzberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Hertzberg. The network helps show where Mark Hertzberg may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Hertzberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 5 | |
| 4 | 2022 | 2 | |
| 5 | 2022 | 2 | |
| 6 | 2021 | 107 | |
| 7 | 2021 | 9 | |
| 8 | 2021 | 3 | |
| 9 | 2018 | 144 | |
| 10 | 2018 | 231 | |
| 11 | Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen | 2017 | 1 |
| 12 | 2017 | 16 | |
| 13 | 2016 | 8 | |
| 14 | 2015 | 21 | |
| 15 | Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studybreakdown → | 2014 | 419 |
| 16 | 2013 | 2 | |
| 17 | 2009 | 25 | |
| 18 | 2006 | 14 | |
| 19 | 2005 | 10 | |
| 20 | 1999 | 13 |
About Mark Hertzberg
Mark Hertzberg is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Dermatology, having authored 166 papers that have together received 3.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (67 papers), Chronic Lymphocytic Leukemia Research (36 papers), Hematopoietic Stem Cell Transplantation (23 papers), CAR-T cell therapy research (17 papers), Acute Myeloid Leukemia Research (16 papers), Platelet Disorders and Treatments (15 papers), Acute Lymphoblastic Leukemia research (15 papers) and Viral-associated cancers and disorders (14 papers). The work is most often cited by research in Hematology (1.1k citations), Genetics (894 citations), Pathology and Forensic Medicine (1.5k citations), Oncology (1.7k citations) and Immunology (605 citations). Mark Hertzberg has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Emmanuel J. Favaloro, David Gottlieb, Ian Kerridge, Alex F. Herrera, Muhıt Özcan, Laurie H. Sehn, Matthew J. Matasar, Tae Min Kim, Andrew McMillan and Grace Ku. Their work appears in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, Biology of Blood and Marrow Transplantation and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.